Júlia Rabelo Santos Ferreira

Bacharel em Nutrição (2019) e Mestre em Saúde Coletiva (área de concentração Epidemiologia) (2021) pela Universidade Federal do Espírito Santo (UFES). Atuou como nutricionista em pesquisa clínica em dois ensaios clínicos para Eli Lilly Company (A Study of Tirzepatide (LY3298176) In Participants After A Lifestyle Weight Loss Program (SURMOUNT-3) e A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight for the Maintenance of Weight Loss (SURMOUNT-4)), em Centro de Diagnóstico e Pesquisa da Osteoporose do Espírito Santo (CEDOES). Atualmente cursando doutorado em Saúde Coletiva (área de concentração Epidemiologia) pela UFES.

Bachelor in Nutrition (2019) and Master in Public Health (Epidemiology concentration area) (2021) by the Federal University of Espírito Santo. He works as a clinical research nutritionist in two clinical trials for Eli Lilly Company (A Study of Tirzepatide (LY3298176) In Participants After A Lifestyle Weight Loss Program (SURMOUNT-3) and A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight for the Maintenance of Weight Loss (SURMOUNT-4)), at the Center for Diagnostic and Research of Osteoporosis of Espírito Santo (CEDOES). In quantitative research, she has experience in population studies and in worker health, with an emphasis on epidemiology of non-communicable chronic diseases, working mainly on the following topics: Hypertriglyceridemic Waist, Metabolic Syndrome and Insulin Resistance.